In this episode of Just the Facts...
Recce Pharmaceuticals (ASX:RCE)
Recce Pharmaceuticals has started dosing patients in its Phase 3 trial of its topical gel R327G for diabetic foot infections in Indonesia. Five sites are now active with enrolment underway for up to 310 patients. The company’s aiming for an interim analysis in early 2026 which could pave the way for accelerated approval — and potentially a commercial launch later that year.
Resolution Minerals (ASX:RML)
Resolution Minerals has been cleared to double the size of its drilling program at the Horse Heaven project in Idaho. The US Forest Service has given the green light to extend Phase One drilling through October, adding eight to ten extra holes for a total of up to 18,000 feet.
American Uranium (ASX:AMU)
American Uranium has secured regulatory approval to begin its resource expansion and infill drilling at the Lo Herma Project in Wyoming — one of the few near-term ISR uranium projects in the US. The program, starting in late 2025, will step out from existing mine units and infill to upgrade resources.
AuKing Mining (ASX:AKN)
AuKing Mining is reporting promising early data from its airborne geophysical survey over the Myoff Creek niobium and rare earths project in British Columbia. The work confirms carbonatite mineralisation in the north — matching historical drilling — and, crucially, highlights new anomalous zones to the south that have never been tested and are now priority targets for follow-up.
#ASXStocks #MiningNews #PharmaNews #ResourceExploration #BiotechAustralia
#GoldExploration #USMining #UraniumMining #ResourceExpansion #Niobium #RareEarths